ArticleCirculation research2017
MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions.
Registry-linked trialAbstract read
In one paragraph
Article in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04399200 (Sleep Apnea Syndrome and Incidence of Major Adverse Cardiac and Cerebrovascular Events), which is not on this map. Cited by 71 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sleep Apnea Syndrome and Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCEs) After a First Stroke
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Non-Coding RNA Profile in the Progression of Carotid Atherosclerosis: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.Pharmacology & therapeutics · 2019Pooled it
- Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids.Theranostics · 2020Trial
- The dark genome in cardiovascular medicine.European heart journal · 2026Review
- Adipose extracellular vesicles carrying miR-210-3p drive macrophage inflammation and nicotine-induced atherosclerosis.iScience · 2026Article
- Review
- Cellular Phenotypic Transformation During Atherosclerosis: The Potential Role of miRNAs as Biomarkers.International journal of molecular sciences · 2025Review
- MicroRNA Expression Profile in Acute Ischemic Stroke.International journal of molecular sciences · 2025Article
- A Review of MicroRNAs and lncRNAs in Atherosclerosis as Well as Some Major Inflammatory Conditions Affecting Atherosclerosis.Biomedicines · 2024Review
- Alteration of circulating miRNAs during myocardial infarction and association with lipid levels.Laboratory medicine · 2024Article
- Utilization of an Artery-on-a-Chip to Unravel Novel Regulators and Therapeutic Targets in Vascular Diseases.Advanced healthcare materials · 2024Article
- Wnt Signaling in Atherosclerosis: Mechanisms to Therapeutic Implications.Biomedicines · 2024Review
- MicroRNA Expression Profile in Acute Ischemic Stroke.Research square · 2024Article
- Circulating CXCL9, monocyte percentage, albumin, and C-reactive protein as a potential, non-invasive, molecular signature of carotid artery disease in 65+ patients with multimorbidity: a pilot study in Age.It.Frontiers in endocrinology · 2024Article
- ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1.Circulation research · 2023Article
- Targeting non-coding RNAs for novel treatment strategies in vascular diseases.European heart journal · 2023Article
- Targeting long non-coding RNA NUDT6 enhances smooth muscle cell survival and limits vascular disease progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Anti-atherosclerosis mechanisms associated with regulation of non-coding RNAs by active monomers of traditional Chinese medicine.Frontiers in pharmacology · 2023Review
- Uncovering Candidate mRNAs, Signaling Pathways and Immune Cells in Atherosclerotic Plaque and Ischemic Stroke.International journal of general medicine · 2023Article
- Knockdown of circ_0113656 assuages oxidized low-density lipoprotein-induced vascular smooth muscle cell injury through the miR-188-3p/IGF2 pathway.Open medicine (Warsaw, Poland) · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Suzanne M EkenFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Hong JinFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Ekaterina ChernogubovaFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Yuhuang LiFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Nancy SimonFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Changyan SunFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Greg KorzunowiczFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Albert BuschFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Alexandra BäcklundFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Cecilia ÖsterholmFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Anton RazuvaevFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Thomas RennéFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Hans Henning EcksteinFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Jaroslav PelisekFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Per ErikssonFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
María González DíezFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Ljubica Perisic MaticFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Isabel N SchellingerFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Uwe RaazFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Nicholas J LeeperFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Göran K HanssonFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Gabrielle Paulsson-BerneFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Ulf HedinFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.).
Lars MaegdefesselFrom the Department of Medicine (S.M.E., H.J., E.C., Y.L., N.S., C.S., G.K., A.B., A.B., P.E., M.G.D., G.K.H., G.P.-B., L.M.) and Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (G.K., C.Ö., A.R., T.R., L.P.M., U.H.); Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL (C.Ö.); Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Germany (T.R.); Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Germany (H.H.E., J.P., L.M.); Heart Center, Georg-August-University Göttingen, Germany (I.N.S., U.R.); and Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA (N.J.L.). lars.maegdefessel@tum.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleIn the search for markers and modulators of vascular disease, microRNAs (miRNAs) have emerged as potent therapeutic targets.
objectiveTo investigate miRNAs of clinical interest in patients with unstable carotid stenosis at risk of stroke. METHODS AND
resultsUsing patient material from the BiKE (Biobank of Karolinska Endarterectomies), we profiled miRNA expression in patients with stable versus unstable carotid plaque. A polymerase chain reaction-based miRNA array of plasma, sampled at the carotid lesion site, identified 8 deregulated miRNAs (miR-15b, miR-29c, miR-30c/d, miR-150, miR-191, miR-210, and miR-500). miR-210 was the most significantly downregulated miRNA in local plasma material. Laser capture microdissection and in situ hybridization revealed a distinct localization of miR-210 in fibrous caps. We confirmed that miR-210 directly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wingless-related integration site) signaling and regulating smooth muscle cell survival, as well as differentiation in advanced atherosclerotic lesions. Substantial changes in arterial miR-210 were detectable in 2 rodent models of vascular remodeling and plaque rupture. Modulating miR-210 in vitro and in vivo improved fibrous cap stability with implications for vascular disease.
conclusionsAn unstable carotid plaque at risk of stroke is characterized by low expression of miR-210. miR-210 contributes to stabilizing carotid plaques through inhibition of APC, ensuring smooth muscle cell survival. We present local delivery of miR-210 as a therapeutic approach for prevention of atherothrombotic vascular events.
Indexed as
AnimalsAtherosclerosisCarotid StenosisCells, CulturedCohort StudiesEndothelial CellsHumansLaser Capture MicrodissectionMaleMiceMice, Inbred C57BLMice, KnockoutMicroRNAsPlaque, AtheroscleroticRatsRats, Sprague-DawleyMicroRNAsMIRN210 microRNA, humanadenomatous polyposis coliatherosclerosiscarotid stenosismicroRNAsstroke
Identifiers
PMID
27895035What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04399200ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.